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Abstract
PRAME/MAPE/OIP4 is a germinal tissue-specific gene that is also expressed at high levels in haematological malig-
nancies and solid tumours. The physiological functions of PRAME in normal and tumour cells are unknown,
although a role in the regulation of retinoic acid signalling has been proposed. Sequence homology and structural
predictions suggest that PRAME is related to the leucine-rich repeat (LRR) family of proteins, which have diverse
functions. Here we review the current knowledge of the structure/function of PRAME and its relevance in
leukaemia.
PRAME is a cancer-testis antigen
PRAME, or preferentially expressed antigen in mela-
noma, was originally identified as a gene encoding a
HLA-A24 restricted antigenic peptide presented to auto-
logous tumour-specific cytotoxic T lymphocytes derived
from a patient with melanoma [1]. PRAME is synon-
ymous with MAPE (melanoma antigen preferentially
expressed in tumours) and OIP4 (OPA-interacting pro-
tein 4), and its expression profile defines it as a cancer-
testis antigen [1]. Cancer-testis antigens (CTAs) are
encoded by non-mutated genes expressed at high levels
in germinal tissues and tumours, but which are absent
from or detected at low levels in other tissues [2].
Examples include the MAGE, BAGE, GAGE and
MAPE/PRAME protein families, all of which have been
detected in tumours of many different histological types
[2]. PRAME may be somewhat different to other can-
cer-testis antigens in that it shows some expression in
normal tissues such as ovary, adrenal, placenta and
endometrium [1]. The C-terminus of human PRAME
(amino acids 453-509) was also identified in a yeast
two-hybrid screen for host cell proteins that bind Neis-
seria gonorrhoeae opacity factors, in this case the OPA-
P protein [3]. Thus PRAME is also known as OIP4
(OPA interacting protein), although the functional
implications of the interaction are unknown. Interest-
ingly, another cancer-testis antigen (OIP5) was isolated
in the same screen [4].
Gene structure, expression and transcripts
The human PRAME gene is encoded on the reverse
strand of chromosome 22 (22q11.22) extending over a
region of approximately 12 kilobases. It is located within
the human immunoglobulin lambda gene locus [5]
which contains a large number of Vl gene segments
used to generate l light chains during B cell develop-
ment. This locus also contains several other non-immu-
noglobulin genes, for example PRAME is situated
between tandem Suppressor of Hairy Wing genes
(SUHW1/ZNF280A and SUHW2/ZNF280B) and a gene
encoding a putative membrane glycoprotein
(POM121L1). Adjacent to POM121L1 is the pseudogene
BCR4 (or BCR4L), which has been identified as a break-
point cluster region implicated in chromosome 22 rear-
rangements [6]. BCR4 shows significant homology to
the 3’ end of the original BCR gene at the Philadelphia
chromosome breakpoint [6]. Interestingly, the BCR4
region is known to be amplified in the CML-derived cell
line K562 [6]. Consistent with this, Northern blots (Fig.
1A) and semi-quantitative PCR data (Fig. 1B) confirmed
that PRAME mRNA is highly elevated in K562 cells in
comparison to other cell types such as Jurkat, U937 and
HL60 which express PRAME at lower levels [1].
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A number of PRAME mRNA transcripts showing dif-
ferential abundance have been detected in normal testis,
malignant tissues and leukaemia-derived cell lines [1,7].
The NCBI database annotates five PRAME mRNA tran-
scripts ranging from 2.1-2.7 kb in length (2141, 2162,
2197, 2220, 2776 bases) and a qPCR study of these 5
mRNAs reported that the two shortest transcripts were
the most abundantly expressed in testis and leukaemia
cell lines [7]. However, sequence databases list at least
17 different PRAME mRNAs, the largest of which is a
3329 base transcript that is clearly detectable in north-
ern blots of total RNA isolated from various cancer cell
lines such as K562, Hela and HL60 (Fig. 1A and refer-
ence 1). Each of the major transcripts contains 6 exons,
four of which contain coding sequence, and all encode
an identical polypeptide of 509 amino acids. Differences
in the 5’ ends of these transcripts suggest the existence
of alternative transcription start sites. This is further
supported by the strong promoter activity in reporter
assays displayed by the sequence around the proximal
transcription start site including exon 1a and the first
intron of the PRAME gene (-165 to +365) [7].
Expressed sequence tags suggest that alternative spli-
cing may produce up to 15 splice variants of PRAME,
some of which potentially encode tissue-specific trun-
cated PRAME proteins, although this remains to be ver-
ified by western blotting. A polyclonal antibody against
PRAME raised by the Coulie group [8] and a commer-
cial antibody (Abcam 32185) used in 2 studies [9,10],
recognise a protein of the expected size (approximately
58kDa) in PRAME-expressing cell lines, although an
apparently non-specific cross-reacting protein is also
detected at around 75kDa [9]. There is a report in the
literature of a monoclonal antibody specific for PRAME,
although the protein detected (33kda) in CLL cells was
below the expected size for full length PRAME [11].
Whether this corresponds to a truncated variant of
PRAME in CLL or interaction with a PRAME-like pro-
tein remains unclear.
Four of the five validated PRAME transcripts contain
unique 5’ untranslated regions (5’ UTRs). Similar
sequence diversity is observed in the 5’UTRs of PRAME
transcripts in other primates, suggesting these sequences
may have functional significance in regulating PRAME
expression in response to metabolic or developmental
signals. As most PRAME 5’ UTRs contain multiple start
and stop codons they would be expected to inhibit pro-
ductive protein synthesis under the canonical model of
cap-dependent translation. In agreement with this, RNA
structure prediction algorithms indicate that human
PRAME 5’ UTRs can form stable secondary structures,
a feature likely to inhibit translation initiation under
normal conditions. Indeed, data from our group indi-
cates that PRAME translation is inhibited by
Figure 1 PRAME expression in leukaemia and lymphoma cell
lines. A: Northern blot analysis of PRAME expression in leukaemia
and lymphoma cell lines. Samples contained 50 μg of total RNA
extracted from tumour cell lines. After Northern blotting,
membranes were hybridised with a 32P-labelled probe consisting of
full-length PRAME coding region, washed at high stringency and
visualised using a phosphorimager. A control probe (b-actin) was
used to confirm equal loading. Both overnight and extended
exposures are shown. B: Semi-quantitative RT-PCR analysis of PRAME
and GAPDH expression in leukaemia and lymphoma cell lines. RNA
was extracted and reversed transcribed using oligo(dT)12-18. cDNA
was amplified using primers: PRAME forward (5’atggaacgaaggcgtttg-
3’), PRAME reverse (5’-ctagttaggcatgaaacaggg-3’), GAPDH forward
(5’-aggtgaaggtcggagtcaac-3’) and GAPDH reverse (5’-
gatgacaagcttcccgttct-3’). An aliquot of the PCR reaction was
removed after 36, 38 and 40 cycles for the PRAME reaction as
indicated, or 35 cycles for the GAPDH control. PCR products were
visualised by gel electrophoresis. C: Induced expression of PRAME in
U937 after DNA demethylation. Leukaemia cell lines U937 (low
levels of PRAME) and K562 (PRAME overexpressed) were cultured in
RPMI plus 10% foetal bovine serum and treated with 1 μM 5-aza-2’-
deoxycytidine for 0-72 hours. RNA was extracted and reverse
transcribed for expression analysis. PRAME mRNA levels were
quantified by real-time qPCR using the following primers: PRAME
254F (tgctgatgaagggacaacat), PRAME 364R (cagcacttgaagtttccacct).
GAPDH primers were as in Fig. 1B. Fold increase in PRAME
expression was calculated by the standard delta-delta CT method,
relative to GAPDH.
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hippuristanol (an inhibitor of the RNA helicase eIF4A
required for translation of structured mRNAs) [FW, KS
& DMH; unpublished].
Regulation of PRAME and expression in
malignancies
While PRAME is absent or expressed at very low levels
in most normal tissues tested, high levels of PRAME
mRNAs are encountered in malignant cells, including
the vast majority of primary and metastatic melanomas
(88% and 95% respectively) [2]. Microarray and PCR
studies have shown that PRAME is absent in normal
haematopoietic tissues including bone marrow, CD34+
sorted bone marrow cells, unsorted peripheral blood
cells and sorted B and T lymphocytes [12-15]. However,
numerous studies have reported highly elevated levels of
PRAME in both acute and chronic leukaemias and non-
Hodgkin’s lymphomas (Fig. 1B and references 12,13,15-
19). PRAME up-regulation was observed in most AML
cases with t(8;21) karyotype and 45% of AML cases with
t(15;17) [13,16,17]. Significant association of PRAME
expression has also been reported in ALL (17-42%)
[18,19], CLL (27%) [11,20], myeloma (23-52%) [21,22]
and chronic phase CML (36%) [12]. In CML, PRAME
expression was found to correlate with disease progres-
sion, showing increased expression in blast crisis as
compared with chronic phase disease [12,15]. PRAME is
also associated with solid organ cancers including skin
[1], breast [23-25], lung [1], head and neck cancers [26]
and neurological neoplasms [27,28].
The regulation of PRAME gene expression is poorly
understood, and thus the molecular basis of its expres-
sion in malignancies is largely unknown. It has been
suggested that AML1-ETO and BCR-ABL fusion pro-
teins may contribute to the up-regulation of PRAME
[13,29], whereas SOX9 has been reported to repress
PRAME expression [30]. However, no correlation was
observed between expression of PRAME and SOX9 in
samples from patients with CML [15]. Like other can-
cer-testis antigens [31,32], the PRAME gene is hyper-
methylated in normal tissues such as bone marrow, but
hypomethylated in malignant cells [7,33-35]. As a conse-
quence, in cell lines such as U937 that show low level
PRAME expression, treatment with DNA demethylators
such as 5’-aza-2’-deoxycytidine can strongly induce
PRAME transcription (Fig. 1C) and studies have shown
that this correlates with demethylation of specific cyto-
sine/guanine dinucleotide rich regions in the PRAME
promoter [7,33,34]. Similarly, methylation-specific PCR
analyses demonstrated that hypomethylation of the
PRAME promoter is significantly more frequent in CML
with blast crisis compared with chronic phase disease
[34]. PRAME mRNA is found frequently in advanced
stages of malignancies such as melanoma [2],
neuroblastoma [28] and breast cancer [23], though not
in the earlier stages of these diseases. Thus, PRAME
may have a role in disease progression, although
whether it is a driver or passenger gene remains to be
established.
Interestingly, a recent comparative genomic hybridisa-
tion study detected microdeletions in the lambda immu-
noglobulin light chain locus (22q11) in 18% of untreated
CLL cases, and also in cases of acute promyelocytic leu-
kaemia and non-Hodgkin’s lymphoma [36]. The mini-
mally deleted region included the ZNF280A, ZNF280B
and PRAME genes and both mono-allelic and bi-allelic
deletions were observed. In some cases the deletion of
the 22q11 locus was the sole chromosomal abnormality
detected, suggesting it may be an important factor in
disease pathogenesis. Absence of PRAME expression in
this CLL subgroup was confirmed by qPCR, but did not
correlate significantly with other clinico-pathological
factors, although a significant correlation was found for
expression of lambda surface light chain in 22q11 dele-
tions [36]. Homozygous deletion of this region
(22q11.22) was also reported in cases of mantle cell lym-
phoma and corresponding cell lines, and the absence of
both PRAME and ZNF280A expression was confirmed
[37]. It remains to be established whether loss of
PRAME or ZNF280A genes are significant contributory
factors in the pathogenesis of leukaemias and non-
Hodgkin’s lymphomas.
The PRAME multigene family
PRAME is a member of a multigene family present in
humans and other mammals. However, orthologous
genes appear to be absent in fish, amphibians and inver-
tebrates. Like several other cancer-testis antigen gene
families, PRAME appears to have undergone multiple
gene duplications during hominid evolution, and at least
22 PRAME-like genes and 10 pseudogenes have been
identified in the human genome [38]. This rapid evolu-
tion is consistent with adaptive (positive) selection simi-
lar to gene clusters involved in immunity and
reproduction, such as the NALP family [39]. Interest-
ingly, several PRAME-like proteins and NALPs have
been proposed to be involved in gametogenesis, follicu-
logenesis and early embryogenesis in the mouse [40].
Oogenesins 1-3 are PRAME-like proteins that show
highly selective expression in mouse ovary, whereas
Oogenesin 4 was detected in both ovary and testis [41].
These proteins show considerable homology to PRAME
and PRAME family members.
PRAME is a leucine rich repeat (LRR) protein
PRAME is a leucine-rich protein of which 21.8% of resi-
dues are leucine or isoleucine. Homology searches reveal
that PRAME and PRAME-like proteins contain leucine-
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Figure 2 PRAME LRR repeats, subcellular localisation and interaction with nuclear receptors. A: Predicted domain structure of the human
PRAME sequence indicating potential Leucine Rich Repeats (LRRs). The LRRs are numbered and indicated by the blue arrows; residues conserved
in typical LRRs are highlighted in bold. The black boxes indicate regions predicted to have a high probability of a-helicity, and two predicted
NLS sequences are underlined. The boxed area in red is a region implicated in interaction with retinoic acid receptors, and potentially contains
LXXLL and CoRNR box-like motifs. B: Subcellular localisation of endogenous PRAME proteins in leukaemia cell lines. Leukaemia cell lines were
cultured as described in the legend to Fig. 1, and harvested onto coverslips using a cytospin centrifuge. Cells were fixed in 4%
paraformaldehyde, permalised with 0.2% Triton X-100 and blocked with 3% PBS prior to application of an a-PRAME antibody (Abcam ab31285)
followed by secondary antibody (Alexa Fluor 594 chicken anti-rabbit IgG - Invitrogen A21442). DNA was stained with a Hoechst stain (Sigma
Aldrich 332581). Images were captured using LSM 510 Meta confocal laser scanning microscope (Zeiss). C: Yeast two-hybrid experiments to
assess interactions of SRC1 nuclear receptor interaction domain (431-761) or full-length PRAME (1-509) with nuclear receptors were performed
using the reporter strain S.cerevisiae L40 as described previously [68,69]. PRAME and SRC1 domains were expressed as LexA fusion proteins.
Nuclear receptor ligand binding domains (RARa 200-464; RXRa 230-467; ERa 282-595; AR 625-919) were expressed as VP16 activation domain
(411-490) fusion proteins, and reporter (b-galactosidase) specific activity was determined as described previously [68,69].
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rich repeats (LRR), and are thus related to the LRR con-
taining protein family (Fig. 2A) [42]. Typical LRR motifs
such as those present in ribonuclease inhibitors are 20-
30 amino acids in length, and contain the consensus
sequence LXXLXLXXN/CX(1/2)L [43]. The LRR repeat
forms a beta sheet followed by an a-helix, and the repeat-
ing units can induce a curved solenoid (horseshoe) fold
with a parallel beta sheet on the concave side and helical
elements on the convex side [44]. However, not all LRRs
fit this consensus and atypical repeats are found among
some families including the PRAME and NALP families.
Secondary and tertiary structure predictions e.g. using
Phyre software [45] suggest that PRAME is likely to
adopt a fold similar to the LRR domains of Toll-like
receptors (TLR3, TLR4) and internalin proteins (refer-
ence [38] and our unpublished analyses). The tertiary
structure of the LRR stack provides an ideal module for
molecular interactions with proteins, nucleic acids and
other ligands; and LRR domains have important func-
tions in cell immunity, cell adhesion and signal transduc-
tion. For example, in cell membrane-associated TLR
proteins the LRR moiety is extracellular, and functions in
sensing pathogen-associated molecular patterns (PAMPs)
[46]. Intracellular LRR proteins, such as NALP family,
are also likely to be activated by PAMPs in antimicrobial
immune responses, resulting in regulation of inflamma-
tion and apoptosis pathways [46]. Thus, the interaction
of PRAME with a bacterial pathogenicity protein is intri-
guing, although, it remains to be established whether
PRAME plays a role in immune response pathways.
Subcellular localisation of PRAME
The subcellular localisation of PRAME has been exam-
ined in a number of studies using different cell lines to
express recombinant epitope-tagged or GFP-tagged
PRAME. Over-expression of PRAME-FLAG and
PRAME-GFP proteins in CHO cells (which do not
express PRAME) was reported to induce aberrant cell
morphology and cell death. However, in transfected cells
expressing low levels of the PRAME-GFP, the protein
was observed to localise to both the nucleus and peri-
nuclear regions [47]. Consistent with this, we have
detected PRAME-GFP and PRAME-FLAG in nuclear
and cytoplasmic compartments, dependent on the cell
type. For example, PRAME-GFP was found both in the
nucleus and cytoplasm of Hela cells, whereas it was
observed to be mainly cytoplasmic in U2OS cells (data
not shown). In addition, in leukaemic cell lines that
express high levels of the native protein, PRAME
appears to be detected both in the nucleus and the cyto-
plasm (Fig. 2B). Consistent with its ability to localise to
the nucleus, PRAME contains several candidate nuclear
localisation signal (NLS) sequences including 157-
KKRKV-161 and 198-KVKRKKNV-205 (Fig. 2A)
Cellular functions of PRAME: repression of
retinoic acid receptor signalling
PRAME has been reported to function as a repressor of
retinoic acid (RA) signalling through interactions with
retinoic acid receptors (RARs) and repression of the
RARb2 gene [8,48]. RARs are important regulators of
haematopoietic differentiation and apoptosis. In the
absence of ligand, RARs can repress their target genes
by recruitment of SMRT and NCOR co-repressor com-
plexes, which have associated histone deacetylase
(HDAC) activities. Binding of retinoic acid induces a
change in the conformation of the RAR ligand binding
domain (LBD), promoting the recruitment of co-activa-
tor complexes with histone acetyltransferase activities.
This can promote transcription of RA target genes, reg-
ulating differentiation, cell cycle arrest and caspase-
dependent apoptosis pathways in responsive cells. The
RARb2 gene is highly up-regulated by RA, and is
believed to be responsible for many of the beneficial
effects of RA in cancer cells. As a consequence, suppres-
sion of RA responsiveness through hypermethylation of
the RARb2 gene promoter, which is a common feature
of tumours, supports the hypothesis that RARb2 has
important tumour suppressor functions. Thus, it was
proposed that repression of RAR function by PRAME
might be an important contributory factor in AML dis-
ease progression [8].
Epping and colleagues demonstrated that over-
expressed TAP-tagged PRAME can be co-immunopreci-
pitated with RARa, with the interaction being depen-
dent on the C-terminus of PRAME [8]. Weak direct
interactions of PRAME and RARa in GST-pulldown
experiments were reported, whereas no binding of
PRAME to ER or RXR was detected [8]. Due to its leu-
cine-rich content, PRAME contains at least seven
sequences matching the consensus of the LXXLL signa-
ture motif found in many nuclear receptor binding pro-
teins [49]. However, only one of these (i.e., 467-
LRELLCE-473, located close to the C-terminus of
PRAME) was found to contribute to interactions with
the RARa LBD in vitro [8]. Unlike most other LXXLL
motif containing cofactors, the interaction of PRAME
with RARa was not reported to be dependent on ligand.
Moreover, mutations in the RARa AF2 helix, which is
essential to generate the LXXLL peptide binding surface,
did not alter the ability of PRAME to repress RA signal-
ling [48].
Nuclear receptor co-repressors such as SMRT and
NCoR contain CoRNR box motifs, which have the
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consensus of LXXX(I/L)XXX(I/L). These motifs mediate
ligand-independent binding to nuclear receptors. Two of
the seven motifs in PRAME, including the most C-term-
inal motif, also fit the CoRNR box consensus (463-
LHARLRELLCELG-475). Thus, it remains to be tested
whether mutations in the RAR LBD that disrupt binding
to CoRNR box peptides would also disrupt the ability of
PRAME to impact on RA signalling. However, until the
structure of the PRAME protein is known, it remains
unclear, whether any of these motifs are available for
protein-protein interactions. In our hands, the binding
of PRAME to the LBDs of RARa or other nuclear
receptors in GST pulldown (data not shown) or yeast
two-hybrid assays (Fig. 2C) is very weak in comparison
with other cofactors such as SRC1. Thus, the possibility
remains that indirect interactions with other proteins
may be important to facilitate the functional interactions
of PRAME and RARs in vivo.
PRAME-mediated suppression of RA signalling was
reported to involve the recruitment of the polycomb
PRC2 complex component, EZH2. Over-expressed
PRAME and EZH2 were shown to co-immunoprecipi-
tate, although whether this is via direct interactions was
not addressed [8]. Knockdown of EZH2 and EED
relieved PRAME-dependent repression of the RARb2
promoter, as did over-expression of a mutant of EZH2
defective in its SET domain methyltransferase function
[8]. In addition to its reported interaction with RARs
and EZH2, yeast two-hybrid screens have identified sev-
eral other proteins that appear to interact with PRAME.
However, the functional significance of reported interac-
tions with nuclear bacterial OPA-P protein [3], the
nuclear kinase STK19 [50], and UBE21 [51] remains to
be investigated.
HDAC inhibitors (HDACi) can induce proliferation
arrest and apoptosis of cancer cell lines, and have shown
promise as anticancer agents in preclinical models and
clinical trials. In a separate study, Epping and colleagues
isolated both RAR and PRAME in a genetic screen for
proteins that could block the effects of HDACi on cell
proliferation [48]. It was shown that ectopic expression
of PRAME blocked the suppressive action of HDACi
compounds in colony formation assays. PRAME also
blocked HDACi-mediated induction of RARb2 and p21
genes, but had no impact on the effects of conventional
chemotherapeutics (such as cisplatin, fluorouracil and
bortezomib in the same model) [48].
The function of PRAME and its effect on gene expres-
sion in leukemic cells remains controversial due to con-
flicting observations in the literature. While in cell-
based models PRAME was reported to down-regulate
genes such as S100A4, RARb2, p21 and Hsp27 [47], a
clinical study reported that expression levels of these
genes were not significantly associated with PRAME
expression in paediatric AMLs [52]. A focussed microar-
ray study of childhood AMLs examining the expression
of 300 stress-related genes reported a correlation
between PRAME expression with up-regulation of mul-
tidrug resistance genes (MRP3 and BCRP) and down-
regulation of pro-apoptotic genes (CIAP2, AKT3, BAK1,
BAX) [53]. However the same genes were unaffected
when PRAME was over-expressed or silenced in cervical
cancer cell lines [52]. Thus, further insight is needed
into the tissue-specific effects of PRAME in gene regula-
tion, and how this is achieved.
Effects of PRAME on cell proliferation and
differentiation
The role of PRAME in proliferation and differentiation
of haematopoietic tissues appears complex. For example,
PRAME expression was associated with reduced prolif-
eration of KG-1 leukaemic cells [47]. In the same study,
knockdown of PRAME caused significantly increased
tumorigenicity of K562 cells in a xenograft model,
which was suggested to be due to reactivation of pro-
apoptotic genes in the absence of PRAME [47]. In a
more recent study, over-expression of PRAME was
found to promote proliferation of various leukaemic cell
lines and inhibit ATRA (all-trans retinoic acid)-induced
myeloid differentiation [15]. However, these effects were
found to be cell line-specific as they were only observed
in cell lines that undergo myeloid differentiation follow-
ing ATRA exposure. When PRAME was over-expressed
in normal haematopoietic progenitor cells in the pre-
sence or absence of ATRA, myeloid differentiation was
inhibited, although proliferation appeared unaffected.
Furthermore, shRNA silencing of PRAME in primary
cells led to increased myeloid differentiation. Thus, the
consequences of induced PRAME expression for prolif-
eration and differentiation of haematopoietic cells
appears to be dependent both on cell lineage, and con-
tributing factors involving other genetic or epigenetic
mechanisms.
Clinical applications of PRAME: risk stratification,
minimal residual disease monitoring and
immunotherapy
Although the role of PRAME in acute leukaemia and
other cancers is complex, it has promise both as a can-
cer biomarker and as a therapeutic target. In AML,
PRAME is usually associated with a favourable response
to chemotherapy and prolonged survival [13,14,54]. This
was initially thought to be due to its expression in leu-
kaemias having favourable prognoses, such as AML M2
with t(8;21), AML M3 with t(15;17) and childhood B-
ALL [13,16,55]. However, PRAME has been reported to
be an independent prognostic factor in AML M3 with t
(15;17) [16] and to be associated with longer overall
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survival, even in karyotypes with generally poor prog-
nosis such as deletion of the long arm of chromosome 7
and monosomy 7 [54]. In contrast, over-expression of
PRAME mRNA is associated with poor prognosis in
solid organ malignancies [23,24,28]. This raises the pos-
sibility that PRAME may have different roles in onco-
genesis or tumour suppression dependent on the
tumour type. Therefore, its usefulness in predicting clin-
ical outcome in solid tumours remains unclear. However
PRAME remains relevant in acute leukaemias for risk
stratification, to monitor residual disease and as a
potential target for immunotherapies.
Disease risk-stratification is imperative in order to best
tailor therapies to meet a patient’s individual needs. At
least a third of patients with de novo AML have normal
cytogenetics and therefore are difficult to risk stratify
[56]. Thus attempts have been made to construct a
molecular stratification model for this group of inter-
mediate risk patients, which includes PRAME expression
[57]. Low PRAME expression at diagnosis was found to
be associated with disease refractory to induction che-
motherapy, shorter relapse-free survival and poorer
overall survival [57]. In cancers other than acute leukae-
mias, PRAME expression is associated with negative
outcomes. Indeed, high PRAME expression is associated
with increased resistance to common chemotherapeutic
regimens in diffuse large B cell lymphomas and Hodg-
kin’s disease [58,59]. Furthermore, it is associated with
failure of second-line therapies and the development of
point mutations in the ABL tyrosine kinase domain in
chronic phase CML [15]. PRAME has also been pro-
posed as a prognostic marker for poor outcome in solid
tumours such as breast and ovarian cancers [10,23,24].
In addition, PRAME has been shown to be a useful indi-
cator of minimal residual disease (MRD) in both acute
and chronic leukaemias [16,18,55,60,61]. While PRAME
mRNA was often significantly over-expressed in bone
marrow samples from patients with newly diagnosed leu-
kaemia (as compared with healthy donors), its expression
level decreased to normal levels in patients who responded
to treatment [17,18,60]. Moreover, increasing levels of
PRAME mRNA have been detected in patients undergoing
relapse, even prior to cytological diagnosis [16,18,60]. This
is particularly advantageous in monitoring MRD in
patients without known genetic markers.
CTAs were originally identified as proteins containing
epitopes that induced cell-mediated immune responses
in cancer patients. Thus they represent promising candi-
dates for the development of immunotherapies specifi-
cally targeting cancer cells [62]. PRAME epitopes were
reported to be recognised by HLA-A24 restricted cyto-
toxic T lymphocytes [1]. Thus, a specific immunother-
apy targeting PRAME might offer a therapeutic benefit
in graft versus leukaemia effects observed after allo-
geneic stem cell transplant, or to prolong a complete
remission achieved by chemotherapy. PRAME has
already been shown to be a prime candidate for such an
immunotherapy, inducing strong immune responses in
healthy volunteers and patients with AML, CML, ALL
and melanoma [9,54,63,64], and could potentially form a
Figure 3 Potential nuclear and cytoplasmic functions of PRAME. Schematic representation depicting interactions of PRAME with nuclear
proteins such as retinoic acid receptor (RAR), polycomb repressor EZH2 and the serine threonine kinase STK19. Interaction with RARs and EZH2
is thought to modulate gene expression and responses to retinoic acid signalling. PRAME also interacts with the outer membrane opacity
protein (OPA-P) from bacterial pathogen N. gonorrhoea, and may also interact with other pathogen-associated microbial patterns (PAMPs)
entering the cytoplasm. In addition, expression of PRAME in cancer cells may allow it to function in sensing molecules associated with cancer or
cancer-related inflammation.
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polyvalent vaccine with other cancer-testis antigens
[65,66]. Unfortunately, like other CTAs, PRAME can
display heterogeneous expression levels within tumours,
which could potentially allow some malignant cells to
escape immunotherapy. Studies have shown that treat-
ment with agents such as 5’-aza-2’-deoxycytidine
[7,33-35] and clofarabine [67] can induce the expression
of CTAs (including PRAME) through DNA demethyla-
tion. Thus, while anti-PRAME vaccines are currently
being evaluated in clinical trials for their efficacy against
PRAME-positive tumours, combination with demethy-
lating agents to maximise CTA expression may be
required for complete elimination of the tumour cells.
Conclusions
Human PRAME and its paralogues are related to LRR
family proteins, some of which are known to have func-
tions in cell immunity and signal transduction. PRAME
may therefore serve as an intracellular sensor of patho-
gen associated molecular particles (PAMPs) or mole-
cules associated with cancer-related inflammation (Fig.
3). To confirm this, it will be important to identify pro-
teins or other molecules that associate with PRAME,
and determine whether PRAME adopts a structure simi-
lar to the LRR domains of TLR or NALP proteins. Mur-
ine orthologues of PRAME show an expression pattern
that is restricted to the zygote, and later to ovary and
testis tissues, suggesting that this family of proteins also
functions in early embryogenesis and gametogenesis.
PRAME expression in cancers may therefore be due to
reactivation of genes associated with ‘stemness’ or pluri-
potency, or in response to signals that activate immune
or autoimmune responses associated with tumours.
The subcellular distribution of PRAME indicates it is
likely to have both nuclear and cytoplasmic functions.
Although direct interactions with retinoic acid receptors
appear weak (Fig. 2), there is substantial evidence that
PRAME may negatively regulate retinoic acid signalling,
through recruitment of polycomb proteins such as
EZH2 to promoter complexes (Fig. 3). It remains to be
determined how these molecular functions of PRAME
exert their effects on differentiation and proliferation of
leukaemic cells. Thus, while the precise molecular func-
tions of PRAME and its role in oncogenesis remain to
be addressed, PRAME continues to serve as both a use-
ful prognostic marker in acute leukaemias and solid
tumours, and an attractive target for potential
immunotherapy.
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